A Personal Journey in Creating Breakthrough Treatments for Disease

By Rich Soll, SVP of Research Service Division at WuXi AppTec (@richsollwx) “As you toil and try to solve some scientific problems along the way, you’re so focused on solving some of these problems that you really don’t necessarily appreciate the impact that your work...

Inside Perspectives on European Biotech Venture Investment – An Interview with Forbion Capital’s Sander Slootweg

By Hui Cai, Vice President of Corporate Alliances and Head of Communications, WuXi AppTec “Since the late 1990’s there’s been a lot of change on the VC side in Europe. Those players that are still here have weathered the adverse market conditions of the past....

Metabomed: A New Venture in Israel’s Start-Up Ecosystem that Tackles Cancer’s Altered Metabolism

By Hui Cai, Vice President of Corporate Alliances and Head of Communications, WuXi AppTec “We want to understand deeply not only the impact of engaging a target that forms a synthetic lethal pair within the framework of a single cell assay, but also how that...

A Golden Age of Drug Discovery in Cancer

By Hui Cai, VP of Corporate Alliances at WuXi AppTec (@HuiCai2) “We are entering into a golden age of drug discovery in cancer. Our understanding of disease, and what causes cancer, has really transformed. …If you want to create an extremely valuable company, I think a...

It’s in the ‘Genes’: The Quest to Develop a Cure for Rare, Genetic Diseases

By Hui Cai, VP of Corporate Alliances at WuXi AppTec (@HuiCai2) “We always felt like gene therapy was coming back, and it sure did. This technology represented a great way for us to come together as a team again to deliver the promise of gene editing...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

Historic Approvals Highlighted at the Second China Innovative Drug Ecosystem Forum...

The recent China Innovative Drug Ecosystem Forum, organized by STA Pharmaceutical, a WuXi AppTec company (WuXi STA), was a resounding success with apt timing...